IAP Antibody (AAP.1): sc-56917

IAP Antibody (AAP.1) is a mouse monoclonal IgG2a antibody that detects intestinal alkaline phosphatase (IAP) in human samples through enzyme-linked immunosorbent assay (ELISA). Anti-IAP antibody (AAP.1) recognizes a crucial digestive brush-border enzyme that plays a significant role in the differentiation of small intestinal epithelial cells, particularly during the absorption of dietary fats. IAP is essential for limiting fat absorption and is involved in the trans-cellular transport and formation of chylomicrons, which are critical for lipid metabolism. IAP operates optimally at high pH levels, where IAP removes phosphate groups from proteins and the 5′ ends of DNA and RNA, thereby influencing various biochemical pathways. IAP is not limited to the intestine; IAP is also found in high concentrations in the liver, bile ducts, placenta, and bone, with different isozymes exhibiting tissue-specific expression. Notably, serum levels of IAP can serve as important biomarkers, as IAP may become elevated in conditions such as liver disease and bone disorders, reflecting tissue damage or disease states. Furthermore, variations in serum IAP levels have been observed among different ABO blood groups, with individuals of blood group O or B showing higher prevalence, indicating a potential link between fatty acid metabolism and blood type. IAP monoclonal antibody (AAP.1) is an invaluable tool for researchers studying the physiological and pathological roles of this enzyme in human health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IAP Antibody (AAP.1) References:

1. Small-molecule pan-IAP antagonists: a patent review.  |  Flygare, JA. and Fairbrother, WJ. 2010. Expert Opin Ther Pat. 20: 251-67. PMID: 20100005
2. Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers.  |  Fulda, S. 2012. Cancer Treat Rev. 38: 760-6. PMID: 22342104
3. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation.  |  Silke, J. and Meier, P. 2013. Cold Spring Harb Perspect Biol. 5: PMID: 23378585
4. Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists.  |  Fulda, S. 2014. Oncogene. 33: 671-6. PMID: 23474760
5. Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.  |  Beug, ST., et al. 2015. Int J Dev Biol. 59: 141-7. PMID: 26374535
6. Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.  |  Cong, H., et al. 2019. J Med Chem. 62: 5750-5772. PMID: 30676015
7. IAP ALS Update on Resuscitation Guidelines During COVID-19 Pandemic.  |  Tiwari, L., et al. 2021. Indian J Pediatr. 88: 469-475. PMID: 32980943
8. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.  |  Crawford, N., et al. 2021. Mol Cancer Ther. 20: 1627-1639. PMID: 34389694
9. Dominant role of DNA methylation over H3K9me3 for IAP silencing in endoderm.  |  Wang, Z., et al. 2022. Nat Commun. 13: 5447. PMID: 36123357
10. Discovery of pan-IAP degraders via a CRBN recruiting mechanism.  |  Park, S., et al. 2023. Eur J Med Chem. 245: 114910. PMID: 36410083

The preferred TNAP antibody is TNAP Antibody (F-4): sc-166261.